ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
8.19
+0.12 (1.49%)
At close: Apr 23, 2026, 4:00 PM EDT
8.14
-0.05 (-0.61%)
Pre-market: Apr 24, 2026, 4:36 AM EDT
ImmunityBio Stock Forecast
Stock Price Forecast
The 7 analysts that cover ImmunityBio stock have a consensus rating of "Strong Buy" and an average price target of $12.57, which forecasts a 53.48% increase in the stock price over the next year. The lowest target is $7.00 and the highest is $23.
Price Target: $12.57 (+53.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +180.83% | Apr 21, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +180.83% | Apr 8, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +180.83% | Mar 26, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +180.83% | Mar 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +180.83% | Mar 17, 2026 |
Financial Forecast
Revenue This Year
213.65M
from 113.29M
Increased by 88.59%
Revenue Next Year
493.86M
from 213.65M
Increased by 131.15%
EPS This Year
-0.26
from -0.38
EPS Next Year
-0.06
from -0.26
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 268.9M | 820.7M | ||||||
| Avg | 213.7M | 493.9M | ||||||
| Low | 169.0M | 277.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 137.4% | 284.1% | ||||||
| Avg | 88.6% | 131.2% | ||||||
| Low | 49.1% | 29.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.19 | 0.16 | ||||||
| Avg | -0.26 | -0.06 | ||||||
| Low | -0.31 | -0.26 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.